This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

New Study Of Cialis® (tadalafil) Tablets Co-administered With Finasteride Meets Primary Endpoint In Men With Lower Urinary Tract Symptoms Of Benign Prostatic Hyperplasia

INDIANAPOLIS, March 18, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) presented results today at the annual European Association of Urology (EAU) Congress in Milan, Italy, of a study that showed Cialis 5 mg once daily co-administered with finasteride significantly improved scores on the International Prostate Symptom Score (IPSS), compared to placebo/finasteride, in men with lower urinary tract symptoms of benign prostatic hyperplasia (LUTS/BPH) and enlarged prostates. On a pre-specified secondary measure, Cialis/finasteride also improved erectile function scores versus placebo/finasteride in those men who had both LUTS/BPH and erectile dysfunction (ED) at baseline.

This is the first study to report co-administration of Cialis and finasteride in men with LUTS/BPH. Cialis is a phosphodiesterase type 5 inhibitor approved by the Food and Drug Administration (FDA) for the signs and symptoms of BPH and both ED and the signs and symptoms of BPH (ED+BPH). Finasteride is a type II 5alpha-reductase inhibitor (5-ARI) approved by the FDA for the treatment of BPH in men with an enlarged prostate.

"Symptomatic improvement with 5-ARI therapy (finasteride) is observed after six to twelve months of treatment; therefore, the study aimed to understand if men with prostatic enlargement experience earlier improvement of BPH symptoms when tadalafil is co-administered with a 5-ARI therapy," said Claus Roehrborn, MD, chairman, Department of Urology, The University of Texas Southwestern Medical Center, who presented the results during the EAU Congress. "These results can help prescribers make better informed decisions when treating their patients."

About the Study The randomized, double-blind, placebo-controlled, 26-week trial assessed the efficacy and safety of Cialis 5 mg for once daily use or placebo co-administered with finasteride in 696 men aged 45 years and older with an International Prostate Symptom Score (IPSS) of at least 13, a urine flow rate (Qmax) of 4 millimeters per second (mL/sec) to 15 mL/sec and a prostate volume at least 30 mL.

The primary measure was the International Prostate Symptom Score (IPSS), a questionnaire evaluating lower urinary tract symptoms (LUTS) occurring during the preceding month where lower scores indicate less severe LUTS. Pre-specified secondary measures included the International Index of Erectile Function-Erectile Function Domain (IIEF-EF), a questionnaire evaluating sexual function where higher scores indicate better erectile function, and the Treatment Satisfaction Scale-Benign Prostatic Hyperplasia (TSS-BPH), a validated, disease-specific 13-item questionnaire used to assess patients' perceptions of satisfaction with efficacy, dosing and side effects, with lower scores indicating greater satisfaction with treatment.

Stock quotes in this article: LLY 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs